علاج متلازمة لامبرت-إيتون الوهنية في الأورام الخبيثة المصاحبة

References

DOI: 10.1177/17562864231213240

• LEMS can be idiopathic (iLEMS; mostly women younger than 50 years) or, less commonly – especially in small-cell lung cancer (SCLC) – as a paraneoplastic disease (pLEMS; mostly in long-time smokers).
• GKS must be used for the treatment of LEMS as a basic immunotherapeutic agent at a dosage appropriate to the severity of the disease for as short a period as possible, taking into account comorbidities, contraindications, and side effects.
• AZA must be used for steroid-sparing therapy.
• Steroids may be used based on expert knowledge in pLEMS; the use of immunotherapeutics is based on clinical symptoms after tumor therapy and long-term prognosis and may be omitted during chemotherapy.
• An absolute lymphocyte count of 600–1000/μl is targeted during therapy.